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In 2013, the Centers for Disease Control and Prevention estimated that approximately two 
million individuals in the United States developed antibiotic-resistant infections. This increasing 
rate of bacterial antibiotic resistance necessitates the development of alternative treatments. 
Gallium-desferrioxamine (Ga-DFO), a gallium-chelated bacterial siderophore, offers a promising 
alternative treatment by exploiting the natural iron-uptake pathway of bacteria to introduce toxic 
gallium ions into the cytoplasm. Previous research demonstrates that the Ga-DFO complex is 
effective against a number of bacterial strains in ideal treatment conditions. The present study 
examines the properties of Ga-DFO and its effectiveness against additional strains in a non-iron-
depleted environment and in mammalian cell culture. Ga-DFO was found to successfully inhibit 
the growth of each bacterial strain tested. It was also effective when added at any time point 
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Properties of a Gallium-Conjugated Siderophore Complex as an Antibacterial Treatment 
         The introduction of antimicrobials transformed the world of medicine. Initially, this new 
class of drugs treated formerly lethal infections with ease. Unfortunately, widespread use of 
antibiotics has created a global selection pressure for antimicrobial-resistant phenotypes that 
threaten our current paradigm of disease treatment. 
A 2014 global analysis of antibiotic usage estimated a 36% increase in antibiotic 
consumption from 2000 to 2010. Anti-Escherichia coli antibiotics (fluoroquinolones and 
cephalosporins) were among the largest absolute increases, of 8.1 billion and 3 billion standard 
units respectively (Van Boeckel, et al., 2014). Unsurprisingly, there has also been an increase in 
the rate of drug resistant E. coli infection in humans (Pitout & Laupland, 2008). There is strong 
evidence the use of  antibiotics to supplement livestock has contributed to human acquisition of 
these drug-resistant strains. They do so by encouraging the development of resistant strains in 
livestock which are subsequently ingested by humans via diet (Corpet, 1988). There is consensus 
amongst researchers that antibiotic overuse should be curbed to prevent long term spread of 
antibiotic resistance (Collignon, 2009; Wintersdorff et al., 2016), while more immediate 
solutions include developing alternative antibacterial treatments. 
E. coli has a well studied mechanisms of resistance to traditional antibiotics such as 
cephalosporins and fluoroquinolones. These include the alteration of drug targets, mutations to 
affect drug accumulation, and expression of drug-targeting plasmids (Jacoby, 2005). These 
mechanisms work synergistically to contribute to antibiotic resistance, and the inhibition of one 
mechanism can lead to recovery of antibiotic susceptibility (Jacoby, 2005). In this study, we 





drugs and prevent drug accumulation, with broader possible applications against other Gram-
negative and Gram-positive bacteria.  
One strategy of drug resistance used by E. coli is prevention of drug accumulation. E. coli 
and other Gram-negative bacteria are able to regulate influx and efflux of extracellular materials 
via expression of outer-membrane porins and efflux pumps, respectively (Nikaido, Rosenburg, 
Foulds, 1983). Outer-membrane porins selectively allow extracellular materials to enter the cell, 
while efflux pumps actively pump out undesirable materials from the cytoplasm. Low outer 
membrane permeability, coupled synergistically with an efflux system, prevent the intracellular 
accumulation of antibiotics (Fernandez & Hancock, 2012). This defense may be bypassed by 
hijacking an essential uptake pathway.  
 The siderophore iron-uptake pathway is a prime candidate for manipulation. 
Siderophores are small iron-chelating molecules that bacteria release into their environment to 
scavenge iron and return to the bacterial cell (Neilands, 1995). This creates an ideal situation for 
input of an antibacterial substance that uses a “Trojan Horse” approach to infiltrate the cell. 
Since iron is essential to many metabolic processes, this iron-scavenging pathway is crucial for 
bacterial survival (Pierre, Fontecave, & Chrichton, 2002). Therefore, any adaptations that would 
decrease the activity of the pathway would also decrease the amount of iron uptake, potentially 
leading to cell death.  
In addition, many bacteria possess receptors for siderophores produced by other 
organisms, and are able to uptake foreign siderophores in order to maximize their iron uptake in 
a phenomenon called siderophore piracy (Luckey et al., 1972). Studies suggest that bacteria may 





This presents the possibility of broad-spectrum effects for a siderophore-chelated antibiotic 
agent.  
         Specifically, chelating toxic metallic ions to a siderophore creates a complex that is able 
to infiltrate the cytoplasm of bacteria like a “Trojan Horse”, reducing a bacterium’s iron intake 
and increasing the concentration of toxic ions to lead to cell death. Gallium has similar binding 
properties and atomic radius as iron, so it is ideal for selection as a “Trojan Horse” metal 
(Minandri et al., 2014). Several studies show that gallium is an effective antibacterial compound 
(Banin et al., 2008; Olakanmi et al., 2013; Minandri et al., 2014). Chelating gallium to a 
siderophore complex would allow greater uptake of the ion through natural iron-uptake 
pathways. Gallium-siderophore complexes also lead to additional toxicity because they compete 
with normal siderophores for entry into the cell, reducing the amount of iron that can be uptaken. 
Once inside, gallium also perturbs iron metabolism and generates oxidative stress, leading to cell 
death (Minadri et. al, 2014). This strategy presents possible advantages over traditional 
antibiotics.  
Existing resistance to conventional antibiotics does not compromise the activity of 
Ga(III) (Minandri et al., 2014). Therefore, the treatment is likely to be effective even against 
bacteria that may have already developed resistance to other antibiotics. Drug-resistant E. coli 
synthesize extended-spectrum beta-lactamase, an enzyme that hydrolyzes beta-lactam antibiotics 
and confers resistance to all penicillins, third-generation cephalosporins, and aztreonam (Shaikh 
et al., 2015). This enzyme is encoded on a plasmid called CTX-M, that can be transferred 
horizontally, spreading resistance between different bacterial population (Shaikh et al., 2015). A 





activity as traditional antibiotics, and thus offers another level of protection against the 
development of resistance. 
The efficacy of such a treatment has been evaluated for several species of bacteria in an 
iron-poor environment (Ahmed et al., 2015). However, current investigations have not 
determined whether Ga-DFO has broad spectrum treatment effects in non-iron-depleted 
environments. Therefore, our experiments will investigate the effectiveness of Ga-DFO against a 
broad spectrum of bacteria in a non-iron-depleted environment as well as in mammalian cell 
culture. Specifically, we will find an estimate of the minimum inhibitory concentration (MIC), or 
approximate lowest concentration of Ga-DFO that inhibits visible growth of each bacteria after 
overnight incubation. In order to fully understand the treatment potential of a Ga-DFO complex, 
this study will address the following research questions: 
Research Questions 
1. Does conjugation with siderophore desferrioxamine (DFO) enhance the antibacterial 
activity of heavy metal ions such as Ga(III)? 
2. What is the MIC estimate of Ga-DFO against a broad spectrum of bacteria?  
3. Is the MIC estimate equally effective when added during different stages of bacterial 
growth? 
a. Does the MIC estimate remain effective at inhibiting bacterial growth over an 
extended time period? 
4. Is Ga-DFO’s effect bacteriostatic or bactericidal?  






The answers to these research questions will serve as a foundation for the future 
development of Ga-DFO as an alternative antimicrobial treatment that does not lead to antibiotic 
resistance.  
We designed three phases of research to answer our research questions and to begin 
determining the viability of Ga-DFO as a commercially applicable antimicrobial.  
Hypotheses 
In the first stage of our research, we propose that chelation to siderophores enhance the 
antibacterial activity Ga(III). We also propose Ga-DFO will be effective against an even broader 
spectrum of bacteria than has previously been studied because bacteria often uptake foreign 
siderophores through siderophore piracy (Traxler et al., 2012). This mechanism can allow Ga-
DFO to enter the cytoplasms of bacteria that are not natural producers of Ga-DFO. 
In the second stage of our research, we propose that Ga-DFO will be effective against 
bacteria during any stage of bacterial growth. We also propose that Ga-DFO will retain its 
antibacterial properties in cultures of previously treated bacteria reinfected after a period of two 
weeks. We chose to investigate reinfection after two weeks because it approximates the long 
term effects of an antibacterial treatment and allows any metabolic processes involving Ga-DFO 
(if they exist) to proceed to completion. Bacteria exposed to antibiotics often undergo autolysis 
(Lewis, 2000), so we postulate that dead bacteria will release cytoplasmic Ga-DFO back into the 
environment, to be uptaken by other cells. Through this mechanism, Ga-DFO in media should 
continue to be effective even after being used to treat bacterial cells in a previous contamination. 
We propose that Ga-DFO will not cause a significant decrease in mammalian cell growth, 
and we will investigate this claim in the third phase of the project. Current literature indicates 





1991). Mammalian cells primarily use proteins such as transferrin and ferritin, not DFO, to 
transport iron (Correnti & Strong, 2012). As a result, we postulate that mammalian cells lack 







Literature Review  
Iron-Uptake as a Target for Antibacterial Treatments 
Bacterial cells utilize iron as an enzymatic cofactor for DNA synthesis and repair, metabolic 
respiration, and oxidative stress response. Iron sources are transported into the Gram-negative 
bacterial cell through specific uptake pathways, which consists of an outer membrane receptor, a 
periplasmic binding protein, and an inner membrane ATP-binding cassette transporter. Under 
physiological conditions, iron can exist in the reduced ferrous (Fe(II)) form or the oxidized ferric 
(Fe(III)) form, making it extremely versatile for incorporation as catalytic centers or electron carriers 
in protein (Krewulak & Vogel, 2008). As such, cells cannot function in an iron deficient 
environment. Since iron uptake is a crucial mechanism to bacterial survival, these defined iron uptake 
routes common to all bacteria could be utilized to bypass the barrier of the cell membrane (Rabsch, 
Voigt, Reissbrodt, Tsolis, & Bäumler, 1999) and introduce toxic metals to the cell, acting as an 
antibacterial treatment.  
Siderophore Complexes 
Siderophores are small iron-scavenging molecules that are secreted by fungi and bacteria 
growing in low-iron environments and uptaken after they have formed a complex with iron 
(Winkelmann, 1991). In bacteria, there are two methods of iron uptake: direct contact between the 
cell and a Fe(III)/heme source (i.e. receptor-mediated iron acquisition from host proteins) or  
siderophore-mediated uptake, the latter of which is the focus of the present study.  The main 
difference between these two methods is that heme and siderophores can be taken up by the bacterial 
cell as intact molecules, while iron must be extracted from host carrier proteins before being 
transported into the cell (Krewulak & Vogel, 2008). Siderophore complexes show significant promise 





Although they lack antibacterial properties themselves, siderophores serve as one of the few transport 
mechanisms capable of penetrating the cell membrane to deliver toxins into the cytoplasm of 
bacterial cells (Zurenko, Truesdell, Yagi, Mourey, & Laborde, 1990). This capability occurs because 
bacteria possess multiple siderophore-specific receptors that allow siderophores and their bound 
substrates to enter and bypass the bacteria’s resistance mechanisms (Rabsch, et al., 1999). Moreover, 
siderophores are capable of entering bacteria other than the ones from which they originated, 
allowing even artificially constructed siderophores to have a wide range of targets (Traxler et al., 
2012). Since the same siderophore could be uptaken by a wide variety of bacteria, a single variety of 
siderophore complex could act as a broad-spectrum antibacterial treatment. This characteristic of the 
treatment attributes to its viability as a potential biopharmaceutical product since a single siderophore 
complex could be used to treat a variety of different infections.    
A variety of  compounds have been considered to address the problem of growing antibiotic 
resistance, such as novel antibiotics and heavy metals. Antibacterial treatments that manipulate these 
routes to bypass the membrane could be highly effective at inhibiting bacterial growth. One area of 
inquiry has investigated siderophores as a trans-membrane shuttle for current antibiotic treatments. 
Although iron-chelating complexes can help antibiotics penetrate into the cell, previous research 
suggests that some of these complexes fail to inhibit bacterial cell growth. Antibiotic-siderophore 
complexes often fail because once an antibiotic binds to the siderophore, it loses its potency and 
becomes ineffective as an antibiotic (Page, Dantier, & Desarbre, 2010). Since antibiotic-siderophore 
complexes are not a feasible antibacterial treatment, alternative applications of siderophores, such as 
a metal-siderophore complexes, can be considered. Specifically, one potential avenue of treatment 
would be to induce bacteria to uptake a metal similar in size to iron but with an associated toxicity.  





A complex with a siderophore and a toxic iron-substituting metal would create a treatment 
that simultaneously deprives bacteria of iron and shuttles toxic ions through the membrane. However, 
an appropriate metal must be selected to create a siderophore complex that will be toxic to bacteria 
while avoiding unintentional toxicity to mammalian cells.  
Silver is a potential metal for use in a siderophore complex. It has been used as a medicinal 
metal since the 1800’s. It has been applied successfully in eye drops to prevent ophthalmia 
neonatorum (neonatal conjunctivitis) in infants (Matejcek & Goldman, 2013), in foil form, and as 
colloidal silver and silver nitrates for burn treatment (Alexander, 2009). The previous success of 
medical silver suggests it has additional potential in an antibacterial setting. Silver’s medicinal 
benefits do not come without disadvantages. When administered orally, silver can occasionally cause 
gastrointestinal problems (Alexander, 2009). When administered intravenously, silver can cause 
convulsions or, even in severe cases, death (Alexander, 2009). The potential of death is severe 
enough to discount the use of silver as a potential metal for use in the siderophore complex. As such, 
it is not an ideal candidate for a treatment that could be administered in the body and was thus 
excluded from this study. 
Zinc has also been considered for an antibacterial agent because of its sheer abundance within 
certain areas of the human body (Ma, Darmawan, Zhang, Zhang, & Bryers, 2013). Since it is 
naturally plentiful in the human body, it may not cause unintended toxicity to mammalian cells. 
However, zinc-complexes must be used at exceedingly high concentrations to effectively treat 
infections, to the point that it becomes toxic to the mammalian host (Ma et al., 2013). When zinc was 
complexed to protoporphyrin IX, it did not inhibit the growth of either S. epidermidis or P. 
aeruginosa. However, when zinc was complex to mesoprotoporphyrin IX, inhibition of bacterial 





bacterial growth, the authors demonstrate that a 12.5x less concentrated treatment of gallium can be 
used to attain the same effect. As such, using zinc is not the most efficient metal to use for 
antibacterial purposes. 
Gallium is an ideal candidate for this use because of its considerable similarity to iron. 
Ga(III)’s atomic radius and binding properties are nearly identical to those of Fe(III) (Ross-Gillespie, 
Weigert, Brown & Kümmerli, 2014), and biological systems have difficulty differentiating between 
the two ions (Ma et al., 2013). As such, gallium can bind easily to iron-scavenging siderophores and 
cross the cellular membrane through uptake pathways intended for iron. Additionally, Ga(III) is not 
able to replace Fe(III) in essential redox-dependent reactions in bacteria because Fe(III) reduces 
readily to Fe(II), but Ga(III) does not reduce to Ga(II) (Ross-Gillespie et al., 2014). Therefore, 
although iron and gallium are similar, gallium would not be an effective replacement to iron in 
biological processes, further suggesting its potential for use in an antibacterial treatment.  
Siderophore-gallium complexes could introduce toxic gallium ions into bacteria instead of the 
necessary supply of iron. In vitro and in vivo data on Ga(III) suggests that some Ga(III) formulations 
could represent an alternative to conventional antimicrobials for treatment of bacterial infections due 
to their toxic effect on bacteria. For example, infections caused by some strains of P. aeruginosa and 
Acinetobacter baumannii are extremely resistant to currently available antibiotic therapies, while both 
species are very sensitive to Ga(III) in vitro as well as in vivo (Minandri et al., 2014). In murine 
models of pulmonary tuberculosis infection, Olakanmi et al. (2013) observed inhibition of M. 
tuberculosis bacterial growth and a significantly increased survival rate in BALB/c mice and SCID 
mice treated with Ga(NO3)3 as compared to control treatments of saline and NaNO3. The 
concentration of gallium administered in this study was determined safe for use in mammalian cells 





treating two different experimental animal infections simulating acute lethal pneumonia and a chronic 
airway biofilm infection (Banin et al., 2008). Therefore, gallium could be an effective method for 
treating bacterial infections. Repurposing Ga(III) as an antibacterial agent offers an opportunity to 
take advantage of the established pharmacological properties of Ga(III)-based formulations, thus 
accelerating clinical testing of its antibacterial properties (Minandri et al., 2014).  
Even before entering the cell, gallium competes with iron for siderophore binding sites, 
thereby limiting the supply of iron available to be uptaken via siderophores (Ross-Gillespie et al., 
2014). While gallium is effective as an antimicrobial agent alone, linking it to a siderophore and 
encouraging greater uptake through manipulation of natural iron-uptake pathways could create a 
treatment that is even more effective in inhibiting bacterial growth. Pathogens such as Pseudomonas 
aeruginosa, Francisella tularensis, Mycobacterium tuberculosis, and E. coli are sensitive to iron 
starvation (Rzhepishevska et al., 2014), so inducing bacteria to uptake a different metal could starve 
the cell of essential iron while introducing toxic ions into the cytoplasm of the bacterial cell. While a 
toxic ion-siderophore complex would not necessarily completely prevent iron uptake, any mutations 
that allow the prevention of uptake of the toxic siderophore would also prevent the uptake of essential 
iron. Therefore,  it could be less likely that bacteria can easily adapt to avoid uptake of the toxic ions. 
After considering all possible metals for use in a metal-siderophore complex, gallium was the 
most appropriate candidate because of its similarity to iron in atomic size and binding properties, as 
well as its previous use as an antibiotic. When implementing a gallium treatment, one must use a 
concentration that is effective at inhibiting bacterial growth without unintentionally harming 
surrounding cells. Too high of a concentration may cause gallium to travel across the cell membrane 
and interfere with iron metabolism in the mammalian cell culture where treatment is being applied, 





concentrations of a gallium-siderophore complex are necessary for treatment since it penetrates the 
cell membrane more effectively through natural iron uptake pathways. Gallium-siderophore 
complexes thus show promise in retaining effectiveness at a concentration that will not harm 
mammalian cells. 
Previous Research on Gallium-Siderophore Complexes 
Previous research has examined metal-siderophore complexes such as Ga-DFO, Ga-cit 
(citrate), Ga-Staphyloferrin A, Ga-PPIX (protoporphyrin IX), Ga–pyoverdine, and Ga–pyochelin. 
Cepaciachelin and dihydroxybenzoyl-serine, two catechol-based siderophores produced by Gram-
negative bacteria, were ruled out for this study after previous research determined that they were no 
more effective than a multitude of simpler, more available siderophores (Kelson et al., 2013). The 
heterologous siderophore DFO is a potential candidate for complex with gallium because of its 
commercial availability and past research on its properties. Specifically, Banin et al. (2008) 
demonstrated that a complex between Ga(III) and DFO was slightly more effective than Ga(III) alone 
in killing P. aeruginosa cells, both in established biofilms and in vivo. It is important to note that 
while that study demonstrated the effective bactericidal properties of Ga-DFO, it did not investigate 
the properties of Ga-DFO with regard to bacterial specificity and robustness against resistance. It also 
investigated the effects of Ga-DFO in a low iron medium, which is less clinically and commercially 
relevant than an iron-sufficient environment. 
Compared to Ga-DFO, Ga-cit exhibits broad activity against many Gram-negative bacteria at 
∼1–5 μg/ml MICs, as well as strong biofilm activity, low drug resistance, and efficacy in vivo 
resulting in higher uptake of gallium by P. aeruginosa (Kelson et al., 2013). Not only that, but the 
Ga–citrate complex also showed higher bacteriostatic and bactericidal activities than Ga-DFO and 





uptake of Ga–citrate by P. aeruginosa cells (Minandri et al., 2014). However, Ga–cit was found to 
exert a negligible inhibitory activity on a number of other species, including E. coli (Minandri et al., 
2014). Citrate-mediated active uptake of Ga(III) may not be sufficient for Ga(III) toxicity against a 
broad spectrum of bacteria. Additionally, with use of Ga-cit, some precipitation can occur at pH 
levels above 7 (Rzhepishevska et al., 2011). Due to these two faults, Ga-cit is not an ideal candidate 
for a broad spectrum antibacterial treatment that is effective in many environmental conditions. 
Staphyloccocus aureus strains such as methicillin resistant strains (MRSA) produce the 
natural siderophore, staphyloferrin. When investigating staphyloferrin as a siderophore component, 
little antibacterial activity was detected, regardless of the metal conjugate, indicating that 
staphyloferrin is not ideal for use in an antibacterial complex (Kelson et al., 2013). Previous research 
indicates that because the siderophore staphyloferrin is native to Staphylococcus aureus, MRSA may 
have the ability to distinguish between Ga-staphyloferrin and Fe-staphyloferrin. Thus, creating a 
gallium complex with a native siderophore may result in poor antimicrobial activity (Kelson et al., 
2013). Bacteria are able to produce their own siderophores and utilize the siderophores produced by 
other bacteria. Desferrioxamine, the native siderophore for Streptomyces pilosus, would therefore be 
a viable option for the purpose of our experiment, since no strains from the Streptomyces genus will 
be studied (Bergeron & Brittenham, 1994). This way, the strains being studied will be less likely to 
differentiate between the iron and gallium complexes. 
Research suggests that Ga-PPIX (protoporphyrin IX chloride) is endowed with strong 
antibacterial activity against a wide range of Gram-positive and Gram-negative bacterial pathogens 
(Minandri et al., 2014). Among the different bacteria samples treated with Ga-PPIX, Bacillus subtilis, 
E. coli, Helicobacter pylori, Listeria monocytogenes, Mycobacterium bovis, Neisseria gonorrhoeae, 





sensitive [MICs ≤ 0.5 μg/ml, corresponding to 0.8 μM Ga(III)]. Yet certain characteristics associated 
with this siderophore complex display its limited efficacy.  For instance, Ga-PPIX was most active 
against bacterial strains grown in an environment with medium or high concentrations of iron 
(Stojiljkovic et al., 1999). In addition, other drawbacks involving bacteria that don’t express haem 
uptake systems or contain cytochromes were shown to significantly reduce the level of antibacterial 
activity.  
Gram-negative species lacking heme uptake systems, such as Salmonella Typhimurium, and 
microorganisms that do not contain cytochromes, such as facultative anaerobes, were found to be 
resistant to Ga-PPIX (Minandri et al., 2014). Moreover, Ga-PPIX showed relatively low aqueous 
solubility, modest toxicity, and a complex synthetic scheme (Kelson et al., 2013). Obligate and 
facultative anaerobic bacteria using fermentation for energy production were found to be resistant to 
Ga-PPIX (Minandri et al., 2014). Ga-pyoverdine and Ga-pyochelin complexes are recognized and 
actively internalized by cognate outer membrane receptors; however, the inhibitory activity of Ga(III) 
on P. aeruginosa was not influenced by the presence of these siderophores and their uptake systems 
(Minandri et al., 2014). The fact that bacteria have already developed resistance to these complexes 
renders them unviable for use in clinical settings. 
After comparison of many possible complexes for use as an antibacterial treatment, we 
determined that Ga-DFO is the most suitable metal-siderophore complex because Ga-DFO presents 
the possibility for broad spectrum effects via siderophore piracy (Traxler, Seyedsayamdost, Clardy, & 
Kolter, 2012), it is easy to acquire, and previous studies have suggested its efficacy as an antibacterial 
agent in vivo. When Ga-DFO was applied to P. aeruginosa, it inhibited growth, prevented biofilm 
formation, and showed bactericidal activity against free-living as well as biofilm cells (Banin et al., 





reduce bacterial growth rates when compared to a treatment of gallium ions alone for four strains of 
bacteria (Ahmed et al., 2015). Intriguingly, Ma et al. (2013) found sub-inhibitory concentration of 
Ga(III) and Ga-DFO (1 μM) can prevent biofilm formation without killing any mammalian cells. The 
finding that treatment with Ga(III) alone can inhibit growth questions validity of the “Trojan Horse” 
model. Thus, further research should be conducted to examine the difference in impact between 
gallium and Ga-DFO treatments. 
Potential Applications 
One potential application for Ga-DFO could be a surface treatment on abiotic surfaces and 
objects. A goal of this project is to contribute to the development of a novel abiotic antibacterial 
treatment. In particular, rates of antibiotic-resistant E.coli infection are rapidly rising worldwide. 
Traditional treatments such as fluoroquinolones and third- or fourth- generation cephalosporins are 
rendered ineffective by the rise of a particular extended spectrum beta-lactamase (ESBL) strain of E. 
coli (Collignon, 2009). A new class of antibiotics such as Ga-DFO present a possible solution for 
treatment of food-borne infections of E. coli.  
Ventilator-associated pneumonia is a common nosocomial infection that significantly 
contributes to morbidity in intensive care unit patients. Catheter-associated urinary tract infection 
(CAUTI) is another common nosocomial infection which is often caused by the formation of biofilm 
on catheter surfaces. He et al. (2012) found that treatment with an antimicrobial spray, called JUC, 
significantly reduced the incidence of CAUTI in hospital patients. JUC spray inhibits the growth of 
microorganisms by creating a positively charged film on the target surface. Addition of Ga-DFO to 
such a treatment could increase the potency of this treatment by adding bactericidal/bacteriostatic 
properties.  Pending further research and development, Ga-DFO also presents possibilities for greater 





and facultative anaerobic microbes (Neilands, 1995). Antimicrobial sprays involving modified 
siderophores could be a novel way to prevent nosocomial infections without contributing to antibiotic 
resistance, especially considering the necessity for iron in biofilm formation (Banin et al., 2005). 
As antibiotic resistance continues to persist and progress, new methods of combating bacteria 
must be developed. Gallium-siderophore complexes are a water-soluble compound with potential for 
development into a spray. In this study, we examine the antibacterial activity of Ga-DFO against a 







In order to answer our research questions, we conducted our project in three phases. In 
Phase I of our project, we examined our first and second research questions. We conducted a 
series of experiments examining the effect of Ga-DFO treatment on various bacterial cell 
cultures including E. coli, Enterobacter aerogenes, S. aureus, and S. typhimurium. For the 
purposes of our research, we defined “treatment” as the administration of a predetermined 
concentration of Ga-DFO into a bacterial culture. We report the MIC estimate of Ga-DFO for a 
selection of motile bacterial cultures in a non-iron-depleted environment.  
         Phase II of our research experiment investigated the properties of Ga-DFO as a 
compound and antibacterial treatment in order to answer research questions three and four. We 





determined whether the Ga-DFO treatment had a bacteriostatic or bactericidal effect using CFU 
analysis. We also determined whether Ga-DFO maintains an antibacterial effect over time by 
reinfecting a treated plate with E. coli after two weeks.  
Phase III of our research examined the applicability of Ga-DFO in mammalian cell 
cultures and addressed the fifth research question. We used Suspension-adapted Freestyle 
Chinese Hamster Ovary (CHO-S) cells and Fibercell Human Embryonic Kidney (HEK) adherent 
cells. We treated non-contaminated cultures of CHO-S cells and HEK cells with applications  of 
Ga-DFO and determined if it caused a decrease in the CHO-S cells’ growth rate. If the treatment 
was found to have no effect on CHO-S cells or HEK cells’ growth rate, we planned to determine 
if Ga-DFO is still effective at treating bacteria in CHO-S and HEK cell culture.  
Bacterial Selection 
 We selected bacterial strains based on their clinical relevance and whether or not they 
produced siderophores. The selected bacteria differ in biosafety levels (BSL) and gram type. 
Gram-positive bacterial resistance to antibiotics is increasing, which is responsible for many 
infections that affect patients in hospitals (Rice, 2006). Gram-negative bacteria are more resistant 
because the outer membrane provides a barrier for antibiotic entrance into the cell (Delcour, 
2008). 
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Table 1. Characteristics of bacterium used. 
 
Data Collection  
 Preparation of Bacterial Cell Culture. All bacterial cell lines were kindly provided by 
the Microbiology Undergraduate Teaching department at the University of Maryland. For all 
experiments, suspension cultures of bacteria were grown in Luria broth [LB] (10g Tryptone, 10g 
NaCl, 5g Yeast Extract per 1L of diH2O) at 37℃. All bacteria were grown to mid-log phase for 
each experiment. We define mid-log as the period in cell culture when bacteria experience 
exponential growth, as evidenced by a sharp increase in optical density readings (OD). Optical 
density readings were measured at 600 nm wavelength. 
 Ga(III)/Ga-DFO Treatment Preparation. Ga-DFO can be synthesized in solution with 
diH2O as a solvent. Equimolar amounts of DFO-mesylate salt (Glentham Life Sciences, Product 
#GP5073) and Ga(Cl)3 (Alfa Aesar, Catalog Number AA43879-06) were added to diH2O, then 
added to an appropriate concentration of LB. We used an adapted chrome azurol S (CAS) assay 
(Ahmed et al., 2015) to confirm complexation.  
CAS assay is a test that utilizes the molecule chrome azurol S (CAS) to detect the 
presence of siderophores in a cell culture. The molecule CAS forms a ternary complex with 





Siderophores compete with the dye to chelate Fe(III). This can be further expressed through the 
following chemical equation: 
  
The ternary complex is represented by FeDye and the siderophore is represented by the L 
symbol. There is a clear indication that the reaction has occurred when the dye color changes 
from blue to red once the iron has detached from the CAS complex and bonded to the 
siderophore. In our experiment, we used desferrioxamine B (DFO-B) as our siderophore and 
gallium as our metallic ion, but the same principles apply because gallium has many of the same 
properties as iron (Ross-Gillespie et al., 2014). We followed the protocol for the CAS Assay as 
referenced in Appendix A1 (Ahmed et al., 2015). 
Phase I: MIC estimate of Ga-DFO 
 We compared the antibacterial activity of a Ga(III) treatment with a Ga-DFO treatment 
via OD readings over a 15 hour microplate fermentation. Both treatments were administered at 
either 0.005M or 0.05M concentrations. After observing our results (Figures 1-4), we proceeded 
to determine the MIC estimate of Ga-DFO against E. coli. We define MIC estimate as an 
approximation of the lowest concentration at which Ga-DFO inhibited the logarithmic growth of 
a given culture of bacteria over a 15 hour microplate fermentation. 
Microplate Fermentation. We used microplate fermentation to determine the effect of 
treatment compounds for each experiment. For microplate fermentation, mid-log cultures of E. 
coli, S. typhimurium, S. aureus and E. aerogenes were diluted to OD600=0.3 and then inoculated 
at a 1:25 ratio with LB  into a 24 well plate (final volume 2.5 mL), then incubated inside a Biotek 





OD600nm). We used the protocol in Appendix A2.1 for microplate preparation and data 
collection. 
         For the purposes of this study, “experiment” refers to one set of microplate fermentations 
performed simultaneously in the same microplate with the same species of bacteria under the 
same treatment. The term “trial” means a single fermentation in a single well of a microplate.  
Phase I controls. To account for possible confounding variables in the results of our 
data, we compared the effect of the Ga-DFO treatment to an no treatment sample and two control 
treatments. The first control was a treatment of free gallium ions at the same concentration as the 
Ga-DFO treatment. The second control treatment was E. coli grown without treatment. This 
served as a point of comparison to examine the effects of the DFO- shuttle mechanism for 
gallium delivery.  
In Phase I, we tested the Ga-DFO treatment on E. coli, E. aerogenes, S. aureus, and S. 
typhimurium. However, we focused on E. coli for subsequent experiments because it is used as a 
model for bacteria of its simplicity, doubling time and ability to grow with different nutrient 
mixtures. It is a single-celled organism that is easy to grow and manipulate. E. coli has a 
doubling time of approximately 20 minutes so it can be reproduced in experiments quickly. The 
small size of its genome provides advantages and its entire genetic sequence has been 
determined. The bacterium grows most rapidly in mixtures that include glucose, salts and 
organic compounds, but it is also able to grow in minimal media that consists of salts, a nitrogen 
source and a carbon source (Cooper, 2000). 
 
 





CFU Analysis. In order to assess bacterial cell viability after treatment, we performed 
cell density analysis by counting colony forming units. This provided a metric to assess the 
bacteriostatic or bactericidal activity of Ga-DFO. E. coli was grown to mid-log phase then 
treated with an equal volume of 0.100 M Ga-DFO LB (final concentration 0.05 M Ga-DFO). 
CFU counts were taken at 5 min, 10 min, and 30 min after treatment using minicolony 
techniques (Sieuwarts et al., 2008). Colony forming units were counted after 18 hours incubation 
at 37℃. From our findings, we proceeded to use 0.05 M Ga-DFO in subsequent experiments. 
Further information on this experiment can be found in the Appendix 3, and the results are 
presented in Figure 6. 
Time-Dependent Dosage. To assess Ga-DFO’s efficacy against bacteria throughout 
various growth phases, a time dosage experiment was conducted. For this experiment, E. coli 
was grown using microplate procedures, and treated with Ga-DFO at 1, 4, 8 and 16, and 24 hours 
after bacterial inoculation. E. coli reaches mid-log phase in approximately 6 hours, so treatment 
at various time points before, during, and after this stage will reveal the potency of Ga-DFO 
against E. coli in various stages of growth. All treatments were performed in quadruplicate. This 
is important to understanding the functionality of Ga-DFO in real world applications. Further 
information on this experiment is available in Appendix 4, and the results are presented in 
Figure 7. 
Two Week Media Transfer An opportunity was also available to adapt the time dosage 
experiment to test whether Ga-DFO has bactericidal or bacteriostatic effect. Upon completion of 
the time dosage experiment, the 24 well plate was incubated at 37℃ for two weeks. Prior to re-
exposure, cell viability was measured using mini-colony CFU analysis. Afterwards, duplicates of 





fermentation. Cell viability was measured again with microplate fermentation. Growth of these 
cultures would show that viable bacteria is still present, indicating that Ga-DFO has a 
bacteriostatic effect and simply stops cell proliferation. No growth would indicate that Ga-DFO 
has a bactericidal effect and kills cells completely. Further information on this experiment is 
available in Appendix 5, and the results are presented in Figure 8. 
Two Week Reinfection. The other duplicates of the wells received an equal volume of 
new LB media (final [Ga-DFO]= 0.025M), and mid-log E. coli diluted to OD=0.3. The plate was 
incubated once more using microplate fermentation. One possible bacterial defense to any 
antibiotic is degradation of the antibiotic. A week-long incubation period allowed Ga-DFO in 
culture to fully react with any possible metabolic enzymes, so that we can also assess the 
potential longevity of the treatment in a practical application. Further information on this 
experiment can be found in Appendix 5, and the results are presented in Figure 9. 
Phase II controls. In order to ensure no contamination was present and growth inhibition 
was as expected, the following controls were implemented. All measurements of cell growth or 
cell viability were taken alongside a “no treatment” sample. For any microplate fermentation, a 
quadruplicate of wells with only LB media was used as a check for contamination in the plate, 
and as a reference for no growth. In addition, a quadruplicate of wells with LB media and E. coli 
was used as a reference for untreated growth. 
 
Phase III: Ga-DFO in Mammalian Cell Culture 
Prior research suggests safe interaction between Ga-DFO and mammalian cells, which is 
crucial for future commercial applications of Ga-DFO but has not yet been studied sufficiently. 
In this study, the effects of Ga-DFO were tested against Human Embryonic Kidney (HEK) cells 





results of phase I, a concentration of 0.005M was used for this phase. This research is intended to 
allow for future research to focus on experiments specific to practical applications of Ga-DFO. 
CHO-S cells were grown in Freestyle Serum Free CHO media + 0.008M L-Glut. HEK 
cells were grown in DMEM with 10% FBS and 1% Penicillin-Streptomycin + 0.008M L-Glut. 
Cells were incubated at 37℃, and viability determined using automated ViCell counter 
(Beckman Coulter) and Trypan Blue staining methods at 1 and 24 hours after inoculation for 
CHO-S cells and at 24 hours after inoculation for HEK cells.  
Phase III controls. To understand the interaction between mammalian cells and Ga-DFO 
we treated mammalian cells from two different species with Ga-DFO. We also compared the 
effects of the Ga-DFO treatment to diluted mammalian cell cultures treated with extra media to 
mimic the decrease in cell density when treatment is added. Cell counts were completed before 
passage to ensure cells are alive and replicating before treatment or dilution. To ensure sterility 
and culture integrity, the only non-media fluid used was sterile filtered ultrapure type 1 water. 
 
Statistical Analysis 
         ANCOVA (one-way analysis of covariance) was used to compare the means of the 
dependent variable based on the independent variable while controlling for the effects of the 
continuous variable of time for all OD measurements taken from microplate fermentation. This 
analysis was carried out for each media condition in order to determine if the differences in cell 
count between treatment groups were statistically significant. The independent variable was 
treatment group (i.e. .05 M Ga-DFO, .005 M Ga-DFO, or Control). The dependent variable was 









A one-way ANCOVA was used to compare the effectiveness of a 0.005M Ga(III) 
treatment and 0.005M and 0.05M Ga-DFO treatments while controlling for time for each 
bacterial strain. The response of E. coli to our treatment is shown in Figure 1. 
 
Figure 1. Growth course for E. coli after administration of 0.005M gallium, 0.005M Ga-DFO, and 0.05M Ga-DFO 
treatment. Treatment was added to liquid culture in the lag phase of growth. 
 
Treatment A [Treatment A], 
(M) 
Treatment B [Treatment B] 
(M) 
P-value 
Ga-DFO 0.05 Ga-DFO 0.005 1.000 
Ga-DFO 0.005 Ga 0.005 0.000* 
Ga-DFO 0.005 Ga 0.005 0.000* 
Ga-DFO 0.05 Control N/A 0.000* 
Ga-DFO 0.005 Control N/A 0.000* 
Table 2. Statistical significance of microplate fermentation of E. coli in the presence of Ga(III) and Ga-DFO 
treatments. Asterisks indicate significant trials. 
 
Gallium treatment alone shows little to no effect on the growth of the bacteria, while 





there is a significant difference in OD [F(4,51)=253.248, p=0.000] between the  treatments of E. 
coli. Post hoc tests showed a significant difference between 0.005M Ga-DFO and 0.005M 
Ga(III) (p=0.000) and 0.05M Ga-DFO and 0.005M Ga(III) (p=0.000).    
 
 
Figure 2. Growth course for E. aerogenes after administration of 0.005M gallium, 0.005M Ga-DFO, and 0.05M Ga-
DFO treatment. Treatment was added to liquid culture in the lag phase of growth. 
 
 
Treatment A [Treatment A], 
(M) 
Treatment B [Treatment B] 
(M) 
P-value 
Ga-DFO 0.05 Ga-DFO 0.005 0.000* 
Ga-DFO 0.05 Ga 0.005 0.000* 
Ga-DFO 0.005 Ga 0.005 0.001* 
Ga-DFO 0.05 Control N/A 0.000* 
Ga-DFO 0.005 Control N/A 0.000* 
Table 3. Statistical significance of microplate fermentation of E. aerogenes in the presence of Ga(III) and Ga-DFO 
treatments. Asterisks indicate significant trials. 
While the gallium treatment shows little to no effect on the growth of the bacteria, 
inhibition of growth is observed at a concentration of 0.05M Ga-DFO. A 0.005M Ga-DFO 





did not completely inhibit all growth.  E. aerogenes growth showed a significant difference in 
OD [F(4,51)=189.854, p=0.000] between the treatments. Specifically, there is a significant 
difference between 0.005M Ga-DFO and 0.005M Ga(III) (p=0.001) and 0.05M Ga-DFO and 
0.005M Ga(III) (p=0.000).   
 
Figure 3. Growth course for S. aureus after administration of 0.005M gallium, 0.005M Ga-DFO, and 0.05M Ga-
DFO treatment. Treatment was added to liquid culture in the lag phase of growth. 
  
Treatment A [Treatment A], 
(M) 
Treatment B [Treatment B] 
(M) 
P-value 
Ga-DFO 0.05 Ga-DFO 0.005 1.000 
Ga-DFO 0.05 Ga 0.005 0.000* 
Ga-DFO 0.005 Ga 0.005 0.000* 
Ga-DFO 0.05 Control N/A 0.000* 
Ga-DFO 0.005 Control N/A 0.000* 
Table 4. Statistical significance of microplate fermentation of S. aureus in the presence of Ga(III) and Ga-DFO 
treatments. Asterisks indicate significant trials. 
 
The gallium treatment shows no effect on S. aureus growth, but an inhibition of growth is 
observed at concentrations of 0.005M and 0.05M Ga-DFO. There is a significant difference in 





difference between 0.005M Ga-DFO and 0.005M Ga(III) (p=0.000) and 0.05M Ga-DFO and 
0.005M Ga(III) (p=0.000).   
  
  
Figure 4. Growth course for S. typhimurium after administration of 0.005M gallium, 0.005M Ga-DFO, and 0.05M 
Ga-DFO treatment. Treatment was added to liquid culture in the lag phase of growth. 
 
 
Treatment A [Treatment A], 
(M) 
Treatment B [Treatment B] 
(M) 
P-value 
Ga-DFO 0.05 Ga-DFO 0.005 1.000 
Ga-DFO 0.05 Ga 0.005 0.000* 
Ga-DFO 0.005 Ga 0.005 0.000* 
Ga-DFO 0.05 Control N/A 0.000* 
Ga-DFO 0.005 Control N/A 0.000* 
Table 5. Statistical significance of microplate fermentation of S. typhimurium in the presence of Ga(III) and Ga-
DFO treatments. Asterisks indicate significant trials. 
 
Gallium treatment shows little to no effect on the growth of the S. Typhimurium. 0.005M 
Ga-DFO leads to a slight reduction in bacterial cell count, and 0.05M Ga-DFO leads to a 1-log 





between the treatments. Post hoc tests show a significant difference between 0.005M Ga-DFO 
and 0.005M Ga(III) (p=0.000) and 0.05M Ga-DFO and 0.005M Ga(III) (p=0.000).  
 
Minimum Inhibitory Concentration of E. coli 
 
 
Figure 5. Growth course of E. coli after administration of 0.05M, 0.0125M, 0.0031M and 0.0078M Ga-DFO 
treatment. Treatment was added to liquid culture in the lag phase of growth. 
 
Treatment A [Treatment A], (M) Treatment B [Treatment B] 
(M) 
P-value 
Control N/A Ga-DFO 0.05 1.000 
Control N/A Ga-DFO 0.0125 0.000* 
Control N/A Ga-DFO 0.0031 0.000* 
Control N/A Ga-DFO 0.00078 0.007* 
Table 6. Statistical analysis for MIC estimate tests. P-value indicates statistical significance of OD difference 
between control and Ga-DFO concentrations. Asterisks indicate significant trials. 
 
Administration of Ga-DFO at a concentration down to 0.0031M completely inhibited 





coli to fall within a range between 0.0031 M and .00078 M. There is a significant difference in 
OD [F(4, 299)= 146.394, p=0.000] between concentrations. Post hoc tests show a significant 
difference between all concentrations of Ga-DFO tested, including 0.0031 M to 0.05 M Ga-DFO 
compared to control (p=0.000) and 0.00078 M Ga-DFO compared to control (0.007). While 
0.00078 M Ga-DFO inhibited growth to a statistically significant degree, it did not completely 
prevent further growth as the higher concentrations did and is therefore below the MIC.  
 
Colony Forming Unit Analysis 
 
Figure 6. Measured cell density of E. coli culture 5 , 10, and 30 min after administration of Ga-DFO. Cell density is 
presented in logarithmic form (base =10). 
 
Treatment A [Treatment A], (M) Treatment B [Treatment B] 
(M) 
P-value 
Control N/A Ga-DFO 0.005 1.000 
Control N/A Ga-DFO 0.05 0.000* 





Table 7. Statistical analysis for CFU analysis. P-values indicate statistical significance of OD difference between 
groups. Asterisks indicate significant trials. 
 
CFU analysis showed negligible bactericidal activity when 0.005 M Ga-DFO was 
administered at mid-log phase, as evidenced by a negligible decrease in colony forming units for 
all time points after treatment. 0.05M Ga-DFO completely eliminated all colony forming units at 
5 min, 10, and 30 min after treatment. There was a significant difference in cell density between 
groups [F(2, 5)= 11.888, p= 0.013]. Post hoc tests show a significant difference between 0.005M 
and 0.05M (p=0.027) and control and 0.05M (p=0.000).   
Time-Dependent Dosage  
 
Figure 7. Growth curve for E. coli with 0.05M Ga-DFO added at 1, 4, 8, 16 hours and 24 hours during the growth 
curve compared to E. coli alone. 
 
Treatment time P-value 
1 hour 0.000* 
4 hours 0.000* 
8 hours 0.000* 
16 hours 0.000* 
Table 8. Growth of E. coli with 0.05M Ga-DFO added at different points during the growth curve. P-values indicate 
the statistical significance of differences in OD between the control (E. coli alone) and the treated culture after time 






Administration of Ga-DFO completely halted growth at its respective time point. 
Statistical analysis indicates there was a significant difference in OD between E. coli alone and 
E. coli with Ga-DFO added at 1 hour [F(1,367)= 2398.092, p=0.000]. There was also a 
significant difference with Ga-DFO added at 4 hours [F(1,343)= 1900.089, p=0.000], 8 hours 
[F(1,311)=528.862, p=0.000] and 16 hours [F(1,247)= 6672.418, p=0.000]. 
Two Week Media Transfer 
 
Figure 8. Growth course of two-week old time dosage cultures refreshed with new LB media. Wells previously 
treated with 0.05M Ga-DFO exhibited no growth, but a previous no treatment well exhibited normal growth. 
 
After 2 weeks of incubation, CFU analysis showed 0 observable colonies. 1, 4, 8 and 16 
hour treatment wells did not exhibit growth after refreshment with new LB media.  In contrast, 2-
week old E. coli with no drug treatment (Null) grew with the introduction of new media as 
shown in Figure 8 below. It exhibited similar growth to a control culture that was grown using 













Two Week Reinfection 
 
Figure 9. The control (new E. coli grown in new media), null (old E. coli grown in new media), 1-hour, 4-hour, 8-
hour and 16-hour wells were reinfected with E. coli two weeks after the time dosage experiment. The growth course 
for the newly introduced E. coli is plotted above.   
 
Well Well P-value 
Control Null 0.000* 
Control 1 hr 0.000* 
Control  4 hr 0.000* 
Control 8 hr 0.000* 
Control 16 hr 0.000* 
Table 9. Statistical analysis for two week reinfection analysis. P-values indicate statistical significance of OD 







In addition, no growth was observed for all wells previously treated with 0.05M Ga-DFO 
and re-inoculated with mid-log E. coli. There is a significant difference in OD [F(5, 359)= 
844.423, p=0.000] between treatment conditions. Post hoc tests show a significant difference 
between the control well and the null, 1 hour, 4 hour, 8 hour and 16 hour wells (p=0.000).   
Mammalian Cell Culture Treatment  
 












0.92 96.6 0.79 97.5 
1 Hour 0.88 96.8 3.22 31.3 
24 Hours 1.84 98.2 1.88 22.4 
Table 10. Viable cell counts and percentage of total cells which are viable for CHO cells treated with 0.005M Ga-
DFO and controls. 
 
 












0.12 85.1 0.12 85.1 
24 Hours 0.35 96.6 0.007 58.3 
Table 11. Viable cell counts and percentage of total cells which are viable for HEK cells treated with 0.005M Ga-
DFO and controls. 
 
 
24 hours after introducing treatment, cell counts and percentage of cells which are viable 





CHO-S cell viability dropped from 97.5% to 31.3% within 1 hour and was 22.4% by 24 hours. In 
contrast, the CHO-S control flask had viabilities of 96.6%, 96.8%, and 98.2% at the same times. 
HEK cell viability and cell counts were 0.12 Viable cells/ml (*10^6) with 85.1% viability for 
both control and treated cultures before treatment or dilution. After 24 hours, HEK control 
increased to 0.35 Viable cells/ml (*10^6) with 96.6% viability while treated HEK decreased to 
0.007 Viable cells/ml (*10^6) with 58.3% viability. 
Images of CHO-S cell culture were taken for both control and treated samples at 1 and 24 
hours after passage and treatment occurred (Figure 10: A-D). Figures 10: A-B were taken of the 
control flask at 1 and 24 hours respectively and appear as expected for a CHO-S culture. Figures 
10: C-D were taken of CHO-S cultures treated with Ga-DFO at 1 hour and 24 hours after 
passage/treatment. It is clear that the treated cultures appear quite different under microscope 












































Figure 10: A-D. Enhanced images of CHO-S suspension. A: Image of control CHO-S suspension at 1 hour after 
passaging. B: Image of control CHO-S suspension at 24 hours after passaging. C: Image of CHO-S suspension + 




         In Phase I of our experiment, we found the MIC estimate of Ga-DFO for E. coli, E. 
aerogenes, S. aureus, and S. typhimurium to be 0.005M Ga-DFO, 0.05M Ga-DFO, 0.005M Ga-







significant difference between 0.005M Ga-DFO and 0.005M Ga(III) (p=0.000), and 0.05M Ga-
DFO and 0.005M Ga(III) (p=0.000) (Figure and Tables 1-4). This indicates DFO complexation 
mediates the antibacterial activity of Ga(III), thus validating the siderophore-uptake model for 
the development of new antibiotics. These findings dispute the supposed toxic activity of Ga(III) 
ions alone, but support previous findings regarding the antibacterial of Ga-DFO. 
 In an attempt to refine the MIC estimate of E. coli, we determined the MIC estimate of 
Ga-DFO to be 0.0031M (Figure 5). Previous research has found the MIC of Ga-DFO to be much 
lower for other bacteria (Minandri et al., 2014), but it is possible that different media 
compositions may have altered the activity of Ga-DFO.  A previously unaddressed question was 
the efficacy of Ga-DFO in non-iron depleted media, since iron could theoretically disrupt the 
bonds between Ga(III) and DFO. We found that administration in complex media did require a 
higher concentration Ga-DFO in order to inhibit growth. However, this decrease in activity may 
or may not be attributed to iron levels in the growth media. 
 
Time-Dependent Dosage 
 The time course experiment showed that Ga-DFO is effective at inhibiting growth of E. 
coli when added at any point during the bacterial growth curve. There was a significant 
difference in OD between E. coli alone and E. coli with Ga-DFO added at 1 hour 
[F(1,367)=2398.092, p=0.000], 4 hours [F(1,343)=1900.089, p=0.000], 8 hours 
[F(1,311)=528.862, p=0.000] and 16 hours [F(1,247)=6672.418, p=0.000]. Therefore, the 
treatment is feasible for application in a real world setting where the growth stage of bacteria is 





replicated to ensure that all time points are not contaminated. Future studies should replicate this 
experiment with several bacterial strains in order to confirm that the effect is conserved.  
 
Two Week Media Transfer 
After 2 weeks of incubation, 1, 4, 8 and 16 hour treatment wells were plated using fresh 
media and no observable colonies were formed. In contrast, the null group (2-week old E. coli 
with no drug treatment) grew with the introduction of new media. This suggests that the Ga-DFO 
treatment has bactericidal activity and killed E. coli instead of just inhibiting further 
proliferation. If the treatment had bacteriostatic activity, bacteria would be able to grow once it 
was introduced to new media and nutrients. 
 
Two Week Reinfection 
When E. coli was reintroduced to a treated culture 2 weeks after treatment, growth was 
significantly inhibited at 1, 4, 8 and 16 hours. Specifically, OD remained approximately 0, 
indicating that no growth occurred. This suggests a lack of metabolic processes that are able to 
inhibit the effects of Ga-DFO. These results show that Ga-DFO offers great promise as a spray 
antibacterial treatment, since it remains effective over the course of two weeks and would 
therefore not require re-application. Future studies should investigate how long exactly Ga-DFO 
remains effective, since longevity of treatment has many implications for the feasibility of a 
commercial product and what it could be used for. They should also make sure that the treatment 
remains stable after reinfection with various strains of bacteria, and even several bacteria at the 





 Since the treatment remained effective after the initial reinfection, we can infer that the 
treated cells lysed and released Ga-DFO into the media to be uptaken by any new bacteria that 
are introduced. However, this theory is not proven by our present study. Another potential 
avenue for future investigations could find the mechanism by which Ga-DFO remains effective 
over time. Specifically, we could measure how many cells lyse after Ga-DFO treatment using 
methods like live/dead cell staining. In order to understand the dynamics of Ga-DFO uptake, we 
could determine the amount of Ga-DFO that is present in the media twelve hours after treatment 
and after two weeks. It would also be useful to determine whether there is a dose dependent 
effect of Ga-DFO’s effectiveness after reinfection. 
Mammalian Cell Culture Treatment  
The drops seen in both Cell Count and Cell Viability suggest that Ga-DFO may be toxic 
to both CHO-S and HEK cells. While post treatment reads were only done at 1 and 24 hours for 
CHO cells and 24 hours for HEK cells, it is possible that cell death continues to occur after 24 
hours unless cells are removed from treated culture. One area of confusion in the cell count data 
is the massive spike in cell count number for treated CHO-S cells at 1 hour. It is likely that the 
ViCell cell counter may have been unable to differentiate the CHO-S cells from small molecules 
in the treatment. However, this does not invalidate the finding because from 1 hour to 24 hours, 
cell count and viability both still decrease from the peaked number considerably. 
The results of Phase III of the experiment fail to confirm the findings of prior literature 
which suggest that Ga-DFO is safe in the presence of mammalian cells. The rapid decrease in 
both cell viability percentage and number suggest Ga-DFO may be toxic to both HEK and CHO-
S cells. However it can not be confirmed that the Ga-DFO is causing the direct death of the 





are inconclusive. It is possible that the mammalian cells died due to a change of culture pH when 





Future Directions  
Mammalian Cell Culture 
While the addition of a 0.005M concentration of Ga-DFO in phase III killed both HEK 
and CHO-S cell cultures, it is unknown whether the treatment itself killed the cells or if cell 
death was a product of the acidic environment caused by adding the treatment. During the 
mammalian cell culture treatment when Ga-DFO in DMEM was added to an HEK culture also in 
DMEM, the media turned from red to yellow as seen in Figure 11 below. DMEM contains 
phenol red as a pH indicator, showing that adding the treatment increased the acidity of the 
media. A future experiment could add a pH neutralizer known to be non-toxic to mammalian 
cells. 
 
Figure 11. Color of DMEM media with HEK cells with Ga-DFO added (left) and without (right). Color indicative 
of phenol red interacting with pH of media. 
An additional future experiment to better test the effect of Ga-DFO on mammalian cells 
could be to rerun the experiment from Phase III but to passage cells out of treated CHO-S and 
HEK cultures after a given amount of time to fresh media without treatment and observe if the 
cells resume growth or not. This experiment could give greater insight into how Ga-DFO affects 






A gallium-siderophore complex has the added benefit of potentially avoiding resistance 
because it manipulates pre-established iron-transport pathways. Also, it is predicted that resistance 
will not be able to combat a gallium-siderophore complex as quickly as it had with antibiotics, if at 
all, because Ga(III) is a multi-target drug that is predicted to impair several Fe(III)-dependent 
functions. Resistance mechanisms such as target mutation, drug modification or development of 
alternative metabolic pathways are unlikely to develop in bacteria to overcome Ga(III) inhibition 
(Minandri et al., 2014). While no claims can definitively be made about the potential for resistance to 
a gallium-siderophore complex, the manipulation of iron-transport pathways and impairment of 
several vital functions makes treatment likely to remain effective longer than traditional antibiotics. 
These predictions were supported by studies investigating the evolutionary potential for 
resistance against a gallium treatment. Researchers compared gallium to two conventional antibiotics 
and used Galleria mellonella used to assay virulence in acute infections in caterpillar hosts (Ross-
Gillespie et al., 2014). The results showed that cultures treated with the antibiotics rose significantly 
in resistance whereas gallium retained effectiveness over time (Ross-Gillespie et al., 2014). This 
indicates that gallium is less susceptible to the development of resistance than conventional 
antibiotics.  
Previous studies indicate that bacteria may have less evolutionary potential to develop 
resistance to gallium treatment compared to traditional antibiotics (Ross-Gillespie et al., 2014; 
Minandri et al., 2014). The combination of nutrient starvation and introduction of harmful metal 
ions by gallium-conjugated siderophore complexes represents a promising strategy for reducing 
rates of bacterial resistance. Mutations that prevents uptake of an iron-substitute would likely be 





potential mechanisms of avoiding the treatment would be maladaptive, it is possible that the 
usual development process of antibiotic resistance would be cut off before it begins. Instead of a 
few bacterial cells acquiring traits that help them survive and then reproducing to pass on those 
traits, bacteria may be unable to mutate in a way that allows them to survive. Metal-siderophore 
complexes could represent an alternative to traditional antibiotics that can be used to address the 
growing problem of antibiotic resistance.  
However, further studies are necessary to confirm these findings. Since Ga-DFO shows 
promise as antibacterial treatment, future investigations should investigate the ability of bacteria 
to evolve resistance to both free gallium and Ga-DFO. This would require testing reinfecting free 
gallium treatment and the Ga-DFO treatment against a strain of bacteria over a considerably 




Since results are inconclusive about the efficacy of Ga-DFO in mammalian cell culture, 
future experiments should investigate using the treatment as an antimicrobial spray as discussed 
above. These experiments could include design and optimization of application technique, 
testing the effectiveness of the spray against different bacterial species or on different surfaces, 
and investigating how long the spray can effectively inhibit bacterial growth. Formulation of a 
Ga-DFO topical treatment could also be an important application of the technology. Similar 
experiments should be conducted to test the efficacy of a topical ointment, particularly 





ointment proves to be stable and effective in many conditions, it could be an attractive treatment 
for use by the military or veterinary care.  
Potency Treatment 
Results indicate that the Ga-DFO treatment is potent against E. coli. Future experiments 
should investigate the degree of potency. The administration of the free gallium treatment and 
the Ga-DFO treatment should be done in different environmental conditions. These 
environmental conditions could include under a UV light, on a solid surface, and in disks. Since 
Ga-DFO shows promise as a treatment against biofilm bacteria in initial studies (Banin et al., 
2008), future experiments should also investigate its effectiveness against biofilms containing a 







A1: CAS protocol 
This protocol is adapted from Schwyn and Neilands (1987) and scaled up and modified for 
convenience. Addition of iron is omitted because this CAS solution is intended to detect gallium. 
Since gallium concentrations will be variable, no gallium is added to the stock solution. 
Materials: 
1 L volumetric flask 
Chrome Azurol S 50% (Aldrich 199532) 
Hexadecyltrimethylammonium bromide (HDTMA) (Sigma H6269) 
Piperazine (make unknown) 
Hydrochloric Acid, concentrated (make unknown) 
CAS Reagent Preparation: 
1. Rinse volumetric flask with 6 M HCl 
2. Rinse volumetric flask with DI water 3 times 
3. Dissolve 43.07 g piperazine in DI water in volumetric flask 
4. Add 62.5 mL concentrated HCl to flask 
5. Add 0.18 g CAS to flask 
6. Add 0.218 g HDTMA to flask 
7. Parafilm top of flask and carefully invert until all phases mix and bubbling subsides. 
Bleed air from top of flask if parafilm is bulging outward. 
8.  Filter resulting solution (0.22 micron is sufficient, non-sterile paper filters work as well) 
9. Store filtered solution in opaque plastic bottle in a cool area 






Gallium trichloride, solid 
DFO mesylate salt, solid 




Early log-phase culture of E. coli 
Early log-phase culture of S. Typhimurium 
Early log-phase culture of S. Aureus 
Early log-phase culture of E. Aerogenes 
Night Before 
1. Inoculate 50 mL flask bacteria 18 hours before planned start of experiment. 
2. Add thawed E.coli stock to 50 mL LB. Shake at 37℃ and 250 RPM. 
3. Repeat step 2 for S. Typhimurium, S. Aureus and E. Aerogenes 
Day of 
4. Transfer 10 mL of E. coli culture from the 50 mL LB flask to the 500 mL LB flask 6 
hours before planned start of the experiment 
5. Measure the OD of the log phase culture and dilute to an OD of 0.3 with PBS 
6. Repeat steps 4-5 for S. Typhimurium, S. Aureus and E. Aerogenes 
7. Add 4.5 mL of 1M Ga-DFO solution to 5.5 mL of 2.2XLB and then perform a 1:10 
dilution with LB to produce 0.05M Ga-DFO treatment 





9. Add 4.5 mL of 1M Ga(Cl)3 solution to 5.5 mL of 2.2XLB and perform two 1:10 dilutions 
with LB to produce 0.005M Ga(Cl)3 solution 
Plate Preparation 
10. Plate on a 24-well plate accordingly, 
  1 2 3 4 5 6 
A 1.13mL 
2.2XLB + 
1.25 mL PBS 




DFO + 0.125 
mL E. coli 
2.38mL 
0.005M Ga-
DFO + 0.125 












1.25 mL PBS 























1.25 mL PBS 









DFO + 0.125 












1.25 mL PBS 

























1.     Activate the microplate reader 
2.     Select the 24-well plate 











A2.2: Minimum Inhibitory Concentration 
Materials: 
Gallium trichloride, solid 
DFO mesylate salt, solid 




Early log-phase culture of E. coli 
Night Before 
1. Inoculate 50 mL flask bacteria 18 hours before planned start of experiment. 
2. Add thawed E.coli stock to 50 mL LB. Shake at 37℃ and 250 RPM. 
Day Of 
3. Transfer 10 mL of culture to 500 mL flask 6 hours before planned start of experiment. 
4.  Weigh out 1.148 g of DFO mesylate and 0.36g Ga(Cl3) and add to 2.50mL of 
autoclaved DI water and 7.50mL 1.33X LB 
5. Measure the OD of the log phase culture and dilute to an OD of 0.3 with PBS 
Plate Preparation 
6. Plate on a 24-well plate accordingly, 
  1 2 3 4 5 6 
A 2.50mL LB 2.40mL LB  2.5mL of 
Ga-DFO 
1.20mL LB  1.20ml LB  1.20mL LB  












C 2.50mL LB 2.40mL LB  1.20mL LB  1.20mL LB  1.20mL LB  1.20mL LB  
D - - 1.20mL LB  1.20mL LB  1.20mL LB  1.20mL LB  
 
7. On the same plate, perform 1:2 dilutions as follows, 
  1 2 3 4 5 6 












































8. On the same plate, add the following, 
  1 2 3 4 5 6 
A - 0.10mL E. 
coli 
1.20 LB + 
0.05mL E. 
coli 
1.20 mL LB 
+ 0.05mL 
E. coli 
1.20 mL LB 
+ 0.05mL E. 
coli 
1.20 mL LB 
+ 0.05mL E. 
coli 
B - - 1.20 mL LB  
+ 0.05mL 
E. coli 
1.20 mL LB 
+ 0.05mL 
E. coli 
1.20 mL LB 
+ 0.05mL E. 
coli 
1.20 mL LB 
+ 0.05mL E. 
coli 
C - 0.10mL E. 
coli 
1.20 mL LB 
+ 0.05mL 
1.20 mL LB 
+ 0.05mL 
1.20 mL LB 
+ 0.05mL E. 
1.20 mL LB 





E. coli E. coli coli coli 
D - - 1.20 mL LB 
+ 0.05mL 
E. coli 
1.20 mL LB 
+ 0.05mL 
E. coli 
1.20 mL LB 
+ 0.05mL E. 
coli 
1.20 mL LB 




1.     Activate the microplate reader 
2.     Select the 24-well plate 
3.     Select 37℃, slow shake, run for 15 hours and collect points every 15 minutes 






A3: CFU Protocol 
Materials: 
Gallium trichloride, solid 
DFO mesylate salt, solid 




96 well plate 
Early-log phase E. coli 
Night Before 
1. Inoculate 50 mL flask bacteria 18 hours before planned start of experiment. Add thawed 
E.coli stock to 50 mLLB. Shake at 37℃ and 250 RPM. 
Day Of 
1. Weigh out 0.657g of DFO mesylate and 0.176g Ga(Cl3) and add to 2.50mL of 
autoclaved DI water and 7.50mL 1.33X LB.  
2. Transfer 10 mL of culture to 500 mL flask 6 hours before planned start of experiment. 
3. Harvest 10 mL of cell culture. This is time 0. 
4. 5 minutes after time 0: 
Take a 10 uL sample from the mixed culture and dilute 1:10 in 90 mL PBS. Do 9 
further serial dilutions to end with a final dilution of 10-10. Plate 10 uL from each 
dilution in an LB plate. 





5. Repeat for time points 15 and 30 minutes after time 0. 







A4: Time-Dependant Dosage 
Materials: 
Gallium trichloride, solid 
DFO mesylate salt, solid 




Early log-phase culture of E. coli 
Night Before 
1. Inoculate 50 mL flask bacteria 18 hours before planned start of experiment. 
 Add thawed E.coli stock to 50 mLLB. Shake at 37℃ and 250 RPM. 
Day of 
2. Transfer 10 mL of culture to 500 mL flask 6 hours before planned start of experiment. 
3.  Weigh out 0.574g of DFO mesylate and 0.18g Ga(Cl3) and add to 2.50mL of autoclaved 
DI water and 7.50mL 1.33X LB 
4. Measure the OD of the log phase culture and dilute to an OD of 0.3 
 Plate Preparation 
5. Plate on a 24-well plate accordingly, 
  1 2 3 4 5 6 
A 2.50mL LB 2.40mL LB 






















B 2.50mL LB 2.40mL LB 


















C 2.50mL LB 2.40mL LB 
+ 0.1mL E. 
coli 




D 2.50mL LB 2.40mL LB 
+0.1mL E. 
coli 












6. Run the plate in the microplate reader for 1 hour 
7. After 1 hour, add the Ga-DFO treatment accordingly, 
  1 2 3 4 5 6 
A - - 1.25mL Ga-
DFO 
Treatment 
- - - 
B - - 1.25mL Ga-
DFO 
Treatment 
- - - 
C - - 1.25mL Ga-
DFO 
Treatment 
- - - 
D - - - - - - 
 
8. After 4 hours (from start of experiment), add the Ga-DFO treatment accordingly, 

















D - - - - - - 
 
9. After 8 hours (from start of experiment), add the Ga-DFO treatment accordingly, 
  1 2 3 4 5 6 












D - - - - - - 
 
10. After 16 hours (from start of experiment), add the Ga-DFO treatment accordingly, 

















D - - - - - - 
 
9.     After 24 hours (from start of experiment), add Ga-DFO treatment accordingly, 
  1 2 3 4 5 6 
A - - - - - - 
B - - - - - - 
C - - - - - - 












1.     Activate the microplate reader 
2.     Select the 24-well plate 
3.     Select 37℃, slow shake, run for 24 hours and collect points every 15 minutes 











A5: Two Week Media Transfer/Reinfection 
Materials 
24-well plate from time-dosage experiment 
LB 




1. After 2 weeks, remove the plate used in “Time-Dependent Dosage Experiment” from the 
incubator 
2. Using a sterile loop, spread the contents in the treatment wells on seperate LB plates  
3. Place the plates in an incubator at 37℃ 
Plate Preparation 
 
1. Using a 24-well plate, plate accordingly, 
 
  1 2 3 4 5 6 
A 2.50mL LB 1.15mL LB 
+ 0.1 mL E. 




+ 0.1 mL E. 




+ 0.1 mL E. 




+ 0.1 mL E. 




+ 0.1 mL E. 
coli + 1.25 
mL old 
culture 
B 2.50mL LB 1.15mL LB 
+ 0.1 mL E. 




+ 0.1 mL E. 




+ 0.1 mL E. 




+ 0.1 mL E. 




+ 0.1 mL E. 
coli + 1.25 
mL old 
culture 
C 2.40mL LB 
+ 0.1mL E. 
1.25 mL LB 
+ 1.25 mL 
1.15mL LB 
+ 1.25 mL 
1.15mL LB 
+ 1.25 mL 
1.15mL LB 
+ 1.25 mL 
1.15mL LB 





coli old culture old culture old culture old culture old culture 
D 2.40mL LB 




+ 1.25 mL 
old culture 
1.15mL LB 
+ 1.25 mL 
old culture 
1.15mL LB 
+ 1.25 mL 
old culture 
1.15mL LB 







1. Activate the microplate reader 
2. Select the 24-well plate 
3. Select 37℃, slow shake, run for 24 hours and collect points every 15 minutes 






A6: Mammalian Cell Culture Experiment 
Materials: 
4x disposable T25 filtered flasks  
3x disposable 125ml filtered shake flasks 
2x 10ml disposable conical tubes 
101ml Freestyle Serum Free CHO media + 0.008M L-Glut 
Suspension-adapted Freestyle Chinese Hamster Ovary (CHO-S) cells 
59ml DMEM with 10% FBS and 1% Penicillin-Streptomycin + 0.008M L-Glut 
Fibercell Human Embryonic Kidney (HEK) Adherent cells 
6x ViCell disposable test tubes 
10mL Trypsin 
Ultrapure type 1 (milli-Q) water 
Gallium trichloride, solid 
DFO mesylate salt, solid 
2x 50ml disposable conicals 
2x 50ml sterile filter conicals 
 
Making Ga-DFO for CHO-S cells: 
1. In a fume hood, add 0.1985g Gallium Chloride(III) to 2.5mL ultrapure type 1 water in a 
50ml disposable conical 
2. Add 0.6289g Desferrioxamine to the same conical, close the conical and mix till all 





3. In a Biosafety cabinet attach a 50mL sterile filter conical to the 50mL conical of Ga-DFO 
and attach the air pump to the filter. With the air pump on, flip the conical and hold until 
all liquid has switched conicals. Remove the air pump and empty conical 
4. Add 7.5mL Freestyle Serum Free CHO media + 0.008M L-Glut to the 50ml conical 
Making Ga-DFO for CHO-S cells: 
1. In a fume hood, add 0.1440g Gallium Chloride(III) to 7.5mL ultrapure type 1 water in a 
50ml disposable conical 
2. Add 0.4562g Desferrioxamine to the same conical, close the conical and mix till all 
precipitate is dissolved 
3. In a Biosafety cabinet attach a 50mL sterile filter conical to the 50ml conical of Ga-DFO 
and attach the air pump to the filter. With the air pump on, flip the conical and hold until 
all liquid has switched conicals. Remove the air pump and empty conical 
4. Add 22.5mL DMEM with 10% FBS and 1% Penicillin-Streptomycin + 0.008M L-Glut to 
the 50ml conical 
CHO-S Cell Line Inoculation: 
1. Retrieve Freestyle Serum Free CHO media + 0.008M L-Glut and place it in a 37℃ water 
bath 
2. Place a pipette gun, multiple pipette gun tips, one disposable 125ml filtered shake flask, 
and a waste container inside a sterile biosafety cabinet 
3. Retrieve cell banked CHO-S Freestyle cells from dewar and thaw cells in 37℃ water bath 
and hand 






5. Add 30mL CHO media to the filtered shake flask using the pipette gun 
6. Add the thawed CHO cells to the same flask using the pipette gun 
7. Place the shake flask in the CO2 incubator at 37℃ on a shaker at 100 RPM for 1-3 days 
until cells are at appropriate seeding density 
HEK Cell Line Inoculation: 
1. Retrieve DMEM with 10% FBS and 1% Penicillin-Streptomycin and place in a 37℃ 
water bath 
2. Place a pipette gun, multiple pipette gun tips, a disposable T25 filtered flask, a disposable 
10mL conical tube, and a waste container inside a sterile biosafety cabinet 
3. Retrieve cell banked HEK Fibercell adherent cells from dewar and thaw cells in 37℃ 
water bath and in hand 
4. Retrieve warmed DMEM and place both the thawed cells and media into the sterile 
biosafety cabinet 
5. Add 5mL DMEM to the 10mL conical 
6. Add HEK cells to the conical using a pipette gun 
7. Centrifuge the conical at 200 RCF for 5 minutes 
8. In the biosafety cabinet, remove the supernatant from the centrifuged conical and 
resuspend the pellet in 5mL fresh DMEM 
9. Using pipette gun, transfer the resuspended pellet in media to the T25 flask 
10. Place the T25 flask in the incubator at 37℃ for 1-3 days until cells are at ~95% 
confluency 
CHO-S Cell Line Passage: 





2. Retrieve the shake flask with CHO cells from 1-3 days prior and place in a sterile 
biosafety cabinet 
3. Place 2 disposable 125mL filtered shake flasks, 1 ViCell disposable test tube, a pipette 
gun, a waste container, and multiple pipette gun tips into the biosafety cabinet 
4. Remove .5ml of media and cells from the inoculated shake flask and transfer it into the 
ViCell test tube  
5. Use the ViCell cell counter to take a preliminary cell count of the media in the test tube 
6. Using the preliminary cell count, determine how much the inoculated CHO culture would 
need to be diluted to achieve a seeding density of 3*10^5 in 30ml of media 
a. Sample calculation: 3mL of 3*10^6 cell count solution (preliminary reading) + 
27mL of solution = 30mL of 3*10^5 cell count solution 
7. Retrive the CHO media from the water bath and place it in the biosafety cabinet 
8. Use the pipette gun to transfer the calculated amount of fresh media into each of the two 
empty shake flasks 
9. Use the pipette gun to transfer the calculated amount of inoculated media (with cells) into 
each of the shake flasks 
10. Place both newly inoculated shake flasks in the CO2 incubator at 37℃ on a shaker at 100 
RPM for 24 hours and dispose of the old shake flask 
HEK Cell Line Passage: 
1. Retrieve the T25 flask with HEK Fibercell cells from 1-3 days prior 
2. Examine the T25 flask under a microscope to check for ~95% confluency. If confluency 
is less than 95%, allow cells to continue growth in the incubator before passaging 





4. Place a pipette gun, multiple pipette gun tips, 9 disposable T25 filtered flasks, a 
disposable 10mL conical tube, 2.5ml Trypsin, and a waste container inside a sterile 
Biosafety Cabinet 
5. Remove and dispose of the media in the inoculated T25 flask 
6. Add 2.5ml of trypsin to the same T25 flask 
7. Place the T25 flask with Trypsin in the CO2 incubator at 37℃ for 3 minutes 
8. After 3 minutes add 1.25ml of DMEM to the incubated T25 flask in the biosafety cabinet 
and pipette the supernatant up and down the side of the flask which cells have adhered to 
9. Remove the supernatant and transfer it to an empty 10mL conical 
10. Centrifuge the conical at 200 RCF for five minutes 
11. After 5 minutes, in the biosafety hood, remove and dispose of the supernatant from the 
centrifuged conical 
12. Resuspend the pellet at the bottom of the conical in 10ml fresh DMEM  
13. Add 4mL of fresh DMEM into each of the 3 empty T25 flasks 
14. Transfer 1mL of media from the conical to each of the same 3 T25 flasks 
15. Place the T25 flasks in the CO2 incubator at 37℃ for 24 hours 
CHO-S Cell and HEK Cell Treatment: 
1. 24 hours after passaging, retrieve the 3 T25 flasks and 2 shake flasks from the CO2 
incubator at 37℃ 
2. Place the DMEM and CHO media in a 37℃ water bath 
3. Place the 3 T25 flasks, 2 shake flasks, 3 ViCell test tubes, a pipette gun, a waste 
container, ultra-pure type 1 water, both stocks of Ga-DFO, and multiple pipette gun tips 





4. Label 1 T25 flask ‘non-diluted/treated’, 1 T25 flask ‘24 hour treated’, and 1 T25 flask ‘24 
hour diluted’ 
5. Remove and dispose of the media in the T25 flask labeled ‘non-diluted/treated’ 
6. Add to the same T25 flask 2.5ml of trypsin 
7. Place the T25 flask with Trypsin in the CO2 incubator at 37℃ for 3 minutes 
8. After 3 minutes add 1.25ml of DMEM to the incubated T25 flask in the biosafety cabinet 
and pipette the supernatant up and down the side of the flask which cells have adhered to 
9. From the same T25 flask remove 0.5ml of media and transfer it into a ViCell test tube to 
serve as an initial cell count for all HEK flasks before treatment 
10. Transfer .5ml of media from each of the inoculated shake flasks into ViCell test tubes for 
pre-treatment cell counts 
11. Use the ViCell cell counter to take cell counts of all 3 test tubes 
12. In the biosafety cabinet, inoculate the shake flask labeled ‘treated’ with 3mL of .055M 
GaDFO 
13. Add 3mL of .0133M GaDFO to the T25 flask labeled with ‘treated’ 
14. Inoculate the remaining shake flask with 3ml CHO media 
15. Dispose of the T25 flask labeled ‘non-diluted/treated’ 
16. Place the remaining 2 T25 flasks and 2 shake flasks in the CO2 incubator at 37℃ with the 
2 shake flasks on a shaker at 100 RPM 
Data Collection: 
1. At 24 hours after step 14 in CHO-S Cell and HEK Cell Treatment was completed above, 
complete the following steps 





3. Place both shake flasks, 4 ViCell test tubes, a pipette gun, a waste container, the 2 T25 
flasks, and multiple pipette gun tips into a sterile biosafety cabinet 
4. Remove and dispose of the media in both T25 flasks 
5. Add to the T25 flasks 2.5ml of trypsin each 
6. Place the T25 flasks with Trypsin in the CO2 incubator at 37℃ for 3 minutes 
7. After 3 minutes add 1.25ml of DMEM to the incubated T25 flasks in the biosafety 
cabinet and pipette the supernatant up and down the side of the flask which cells have 
adhered to 
8. From the same T25 flasks remove .5ml of media and transfer it in to 2 ViCell test tubes 
9. Transfer .5ml of media from each of the shake flasks into 2 ViCell test tubes 
10. Use the ViCell cell counter to take cell counts of all 4 test tubes 
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